Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP)

Marcin Okroj, Linda Mark, Anna Stokowska, Scott Wong, Nicola Rose, David J. Blackbourn, Bruno O. Villoutreix, O. Brad Spiller, Anna M. Blom

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Rhesus rhadinovirus (RRV) is currently the closest known, fully sequenced homolog of human Kaposi sarcoma-associated herpesvirus. Both these viruses encode complement inhibitors as follows: Kaposi sarcoma-associated herpesvirus-complement control protein (KCP) and RRV-complement control protein (RCP). Previously we characterized in detail the functional properties of KCP as a complement inhibitor. Here, we performed comparative analyses for two variants of RCP protein, encoded by RRV strains H26-95 and 17577. Both RCP variants and KCP inhibited human and rhesus complement when tested in hemolytic assays measuring all steps ofactivation via the classical and the alternative pathway. RCP variants from both RRV strains supported C3b and C4b degradation by factor I and decay acceleration of the classical C3 convertase, similar to KCP. Additionally, the 17577 RCP variant accelerated decay of the alternative C3 convertase, which was not seen for KCP. In contrast to KCP, RCP showed no affinity to heparin and is the first described complement inhibitor in which the binding site for C3b/C4b does not interact with heparin. Molecular modeling shows a structural disruption in the region of RCP that corresponds to the KCP-heparin-binding site. This makes RRV a superior model for future in vivo investigations of complement evasion, as RCP does not play a supportive role in viral attachment as KCP does.

Original languageEnglish (US)
Pages (from-to)505-514
Number of pages10
JournalJournal of Biological Chemistry
Volume284
Issue number1
DOIs
StatePublished - Jan 2 2009

Fingerprint

Rhadinovirus
Complement System Proteins
Complement Inactivating Agents
Proteins
Heparin
Classical Pathway Complement C3 Convertase
Complement C3-C5 Convertases
Binding Sites
Molecular modeling
Viruses
Human Herpesvirus 8
Assays

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). / Okroj, Marcin; Mark, Linda; Stokowska, Anna; Wong, Scott; Rose, Nicola; Blackbourn, David J.; Villoutreix, Bruno O.; Brad Spiller, O.; Blom, Anna M.

In: Journal of Biological Chemistry, Vol. 284, No. 1, 02.01.2009, p. 505-514.

Research output: Contribution to journalArticle

Okroj, M, Mark, L, Stokowska, A, Wong, S, Rose, N, Blackbourn, DJ, Villoutreix, BO, Brad Spiller, O & Blom, AM 2009, 'Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP)', Journal of Biological Chemistry, vol. 284, no. 1, pp. 505-514. https://doi.org/10.1074/jbc.M806669200
Okroj, Marcin ; Mark, Linda ; Stokowska, Anna ; Wong, Scott ; Rose, Nicola ; Blackbourn, David J. ; Villoutreix, Bruno O. ; Brad Spiller, O. ; Blom, Anna M. / Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). In: Journal of Biological Chemistry. 2009 ; Vol. 284, No. 1. pp. 505-514.
@article{7fde5faf82374f3eb4d1d1b5063c88f4,
title = "Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP)",
abstract = "Rhesus rhadinovirus (RRV) is currently the closest known, fully sequenced homolog of human Kaposi sarcoma-associated herpesvirus. Both these viruses encode complement inhibitors as follows: Kaposi sarcoma-associated herpesvirus-complement control protein (KCP) and RRV-complement control protein (RCP). Previously we characterized in detail the functional properties of KCP as a complement inhibitor. Here, we performed comparative analyses for two variants of RCP protein, encoded by RRV strains H26-95 and 17577. Both RCP variants and KCP inhibited human and rhesus complement when tested in hemolytic assays measuring all steps ofactivation via the classical and the alternative pathway. RCP variants from both RRV strains supported C3b and C4b degradation by factor I and decay acceleration of the classical C3 convertase, similar to KCP. Additionally, the 17577 RCP variant accelerated decay of the alternative C3 convertase, which was not seen for KCP. In contrast to KCP, RCP showed no affinity to heparin and is the first described complement inhibitor in which the binding site for C3b/C4b does not interact with heparin. Molecular modeling shows a structural disruption in the region of RCP that corresponds to the KCP-heparin-binding site. This makes RRV a superior model for future in vivo investigations of complement evasion, as RCP does not play a supportive role in viral attachment as KCP does.",
author = "Marcin Okroj and Linda Mark and Anna Stokowska and Scott Wong and Nicola Rose and Blackbourn, {David J.} and Villoutreix, {Bruno O.} and {Brad Spiller}, O. and Blom, {Anna M.}",
year = "2009",
month = "1",
day = "2",
doi = "10.1074/jbc.M806669200",
language = "English (US)",
volume = "284",
pages = "505--514",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

TY - JOUR

T1 - Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP)

AU - Okroj, Marcin

AU - Mark, Linda

AU - Stokowska, Anna

AU - Wong, Scott

AU - Rose, Nicola

AU - Blackbourn, David J.

AU - Villoutreix, Bruno O.

AU - Brad Spiller, O.

AU - Blom, Anna M.

PY - 2009/1/2

Y1 - 2009/1/2

N2 - Rhesus rhadinovirus (RRV) is currently the closest known, fully sequenced homolog of human Kaposi sarcoma-associated herpesvirus. Both these viruses encode complement inhibitors as follows: Kaposi sarcoma-associated herpesvirus-complement control protein (KCP) and RRV-complement control protein (RCP). Previously we characterized in detail the functional properties of KCP as a complement inhibitor. Here, we performed comparative analyses for two variants of RCP protein, encoded by RRV strains H26-95 and 17577. Both RCP variants and KCP inhibited human and rhesus complement when tested in hemolytic assays measuring all steps ofactivation via the classical and the alternative pathway. RCP variants from both RRV strains supported C3b and C4b degradation by factor I and decay acceleration of the classical C3 convertase, similar to KCP. Additionally, the 17577 RCP variant accelerated decay of the alternative C3 convertase, which was not seen for KCP. In contrast to KCP, RCP showed no affinity to heparin and is the first described complement inhibitor in which the binding site for C3b/C4b does not interact with heparin. Molecular modeling shows a structural disruption in the region of RCP that corresponds to the KCP-heparin-binding site. This makes RRV a superior model for future in vivo investigations of complement evasion, as RCP does not play a supportive role in viral attachment as KCP does.

AB - Rhesus rhadinovirus (RRV) is currently the closest known, fully sequenced homolog of human Kaposi sarcoma-associated herpesvirus. Both these viruses encode complement inhibitors as follows: Kaposi sarcoma-associated herpesvirus-complement control protein (KCP) and RRV-complement control protein (RCP). Previously we characterized in detail the functional properties of KCP as a complement inhibitor. Here, we performed comparative analyses for two variants of RCP protein, encoded by RRV strains H26-95 and 17577. Both RCP variants and KCP inhibited human and rhesus complement when tested in hemolytic assays measuring all steps ofactivation via the classical and the alternative pathway. RCP variants from both RRV strains supported C3b and C4b degradation by factor I and decay acceleration of the classical C3 convertase, similar to KCP. Additionally, the 17577 RCP variant accelerated decay of the alternative C3 convertase, which was not seen for KCP. In contrast to KCP, RCP showed no affinity to heparin and is the first described complement inhibitor in which the binding site for C3b/C4b does not interact with heparin. Molecular modeling shows a structural disruption in the region of RCP that corresponds to the KCP-heparin-binding site. This makes RRV a superior model for future in vivo investigations of complement evasion, as RCP does not play a supportive role in viral attachment as KCP does.

UR - http://www.scopus.com/inward/record.url?scp=58649105573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58649105573&partnerID=8YFLogxK

U2 - 10.1074/jbc.M806669200

DO - 10.1074/jbc.M806669200

M3 - Article

C2 - 18990693

AN - SCOPUS:58649105573

VL - 284

SP - 505

EP - 514

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 1

ER -